Healthcare -
Biotechnology - NASDAQ - US
$ 3.03
1 %
$ 993 M
Market Cap
-2.37
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Iovance Biotherapeutics, Inc.
| Current Assets | 457 M |
| Cash & Short-Term Investments | 324 M |
| Receivables | 69.3 M |
| Other Current Assets | 63.9 M |
| Non-Current Assets | 453 M |
| Long-Term Investments | 0 |
| PP&E | 164 M |
| Other Non-Current Assets | 289 M |
| Current Liabilities | 122 M |
| Accounts Payable | 27.5 M |
| Short-Term Debt | 12.9 M |
| Other Current Liabilities | 81.9 M |
| Non-Current Liabilities | 77.7 M |
| Long-Term Debt | 44.4 M |
| Other Non-Current Liabilities | 33.3 M |
EFFICIENCY
Earnings Waterfall
Iovance Biotherapeutics, Inc.
| Revenue | 164 M |
| Cost Of Revenue | 124 M |
| Gross Profit | 40.1 M |
| Operating Expenses | 435 M |
| Operating Income | -395 M |
| Other Expenses | -23.1 M |
| Net Income | -372 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Iovance Biotherapeutics, Inc.
| Net Income | -372 M |
| Depreciation & Amortization | 31.6 M |
| Capital Expenditures | -11.1 M |
| Stock-Based Compensation | 110 M |
| Change in Working Capital | -123 M |
| Others | -2.29 M |
| Free Cash Flow | -364 M |
Wall Street Analysts Price Targets
Iovance Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for IOVA of $17.3 , with forecasts ranging from
a
low of
$6 to a high of $28 .
IOVA Lowest Price Target
Wall Street Target
6 USD
98.02%
IOVA Average Price Target
Wall Street Target
17.3 USD
471.37%
IOVA Highest Price Target
Wall Street Target
28 USD
824.09%
4. DIVIDEND
ANALYSIS
IOVA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Iovance Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
503 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
fool.com
- 6 days ago
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
fool.com
- 3 weeks ago
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
fool.com
- 3 weeks ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 308,710 shares of Iovance's common stock to forty-three new, non-executive employees.
globenewswire.com
- 3 weeks ago
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
fool.com
- 1 month ago
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
seekingalpha.com
- 1 month ago
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
zacks.com
- 1 month ago
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni Benjamin - Citizens JMP David Dai - UBS Andrew Tsai - Jefferies Operator Good day and thank you for standing by. Welcome everyone to the Iovance Biotherapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
seekingalpha.com
- 1 month ago
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
zacks.com
- 1 month ago
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M
globenewswire.com
- 1 month ago
What's in Store for These 5 Biotech Stocks This Earnings Season?
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
zacks.com
- 1 month ago
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
8. Profile
Summary
Iovance Biotherapeutics, Inc. IOVA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 993 M
Dividend Yield
0.00%
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Contact
825 Industrial Road, San Carlos, CA, 94070
https://www.iovance.com
IPO
Date
Oct. 15, 2010
Employees
838
Officers
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Dr. Igor P. Bilinsky Ph.D.
Chief Operating Officer
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer
Mr. Howard B. Johnson M.B.A.
Chief Business Officer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology
Ms. Sara Pellegrino
Senior Vice President of Investor Relations & Corporate Communications
Dr. Raj K. Puri M.D., Ph.D.
Chief Regulatory Officer
Ms. Tracy Winton
Executive Vice President of Human Resources
Mr. Kevin Smyth
Executive Vice President of Quality